Bifemelane

Bifemelane
	File:Bifemelane.svg
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N06AX08 (WHO) ;
Identifiers
	IUPAC name N-methyl-4-[2-(phenylmethyl)phenoxy]butan-1-amine;
CAS Number	90293-01-9 ;
PubChem CID	2377;
ChemSpider	2286 ;
UNII	Z4501GN13G;
ChEMBL	ChEMBL1192517 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C18H23NO
Molar mass	269.381 g/mol
3D model (JSmol)	Interactive image;
	SMILES O(c1ccccc1Cc2ccccc2)CCCCNC;
	InChI InChI=1S/C18H23NO/c1-19-13-7-8-14-20-18-12-6-5-11-17(18)15-16-9-3-2-4-10-16/h2-6,9-12,19H,7-8,13-15H2,1H3 ; Key:QSQQPMHPCBLLGX-UHFFFAOYSA-N ;
(what is this?) (verify)

Bifemelane (Alnert, Celeport) is a pharmaceutical drug used in the treatment of senile dementia in Japan.^[1] It has nootropic, neuroprotective, and antidepressant effects, and acts through the cholinergic system in the brain.^[2]^[3]^[4] Bifemelane is also useful for the treatment of glaucoma.^[5]

References

↑ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 265. ISBN 0-412-46630-9.
↑ Kondo, Y; Ogawa, N; Asanuma, M; Matsuura, K; Nishibayashi, K; Iwata, E (1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience research. 24 (4): 409–14. doi:10.1016/0168-0102(95)01017-3. PMID 8861111.
↑ Egashira, T; Takayama, F; Yamanaka, Y (1996). "Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries". Japanese journal of pharmacology. 72 (1): 57–65. doi:10.1254/jjp.72.57. PMID 8902600.
↑ Moryl E, Danysz W, Quack G (June 1993). "Potential antidepressive properties of amantadine, memantine and bifemelane". Pharmacology & Toxicology. 72 (6): 394–7. doi:10.1111/j.1600-0773.1993.tb01351.x. PMID 8361950.
↑ Shigemitsu, T; Majima, Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical therapeutics. 18 (1): 106–13. doi:10.1016/S0149-2918(96)80183-4. PMID 8851457.